Inhibitory effects of sesamin on CYP2C9-dependent 7-hydroxylation of S-warfarin

被引:3
作者
Fujii, Miharu [1 ]
Yasuda, Kaori [1 ]
Sakaki, Toshiyuki [1 ]
机构
[1] Toyama Prefectural Univ, Fac Engn, Dept Pharmaceut Engn, 5180 Kurokawa, Imizu, Toyama 9390398, Japan
关键词
Sesamin; Warfarin; CYP2C9; Human liver microsomes; Competitive inhibition; ANTIOXIDATIVE METABOLITES; EPISESAMIN; LIVER; CYTOCHROME-P450; LIGNAN;
D O I
10.1016/j.dmpk.2020.05.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A recent report demonstrated that sesamin strongly and non-competitively inhibits S-warfarin 7-hydroxylation activity in human liver microsomes with a K-i value of 0.2 mu M. This finding suggests that sesamin predominantly binds to CYP2C9 at another site for which it has a higher affinity than its affinity for the active site, thereby inhibiting the activity of CYP2C9 non-competitively. In this study, we found that sesamin competitively inhibited the 7-hydroxylation activity of S-warfarin in human liver microsomes with a K-i value of 15.7 mu M. In addition, the recombinant CYP2C9-dependent 7-hydroxylation activity of S-warfarin was competitively inhibited by sesamin with a Ki value of 13.1 mu M. These results are consistent with the fact that sesamin is a good substrate of CYP2C9, and its activity follows Michaelis-Menten kinetics. As the plasma concentration of sesamin after its administration is usually lower than 0.01 mu M, the inhibition of S-warfarin metabolism by sesamin does not appear to be severe. (C) 2020 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:368 / 373
页数:6
相关论文
共 42 条
[21]   Genetically based impairment in CYP2C8-and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: Is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? [J].
Agundez, Jose A. G. ;
Garcia-Martin, Elena ;
Martinez, Carmen .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (06) :607-620
[22]   1-Aminobenzotriazole Coincubated with (S)-Warfarin Results in Potent Inactivation of CYP2C9 [J].
Sodhi, Jasleen K. ;
Ford, Kevin A. ;
Mukadam, Sophie ;
Wong, Susan ;
Hop, Cornelis E. C. A. ;
Khojasteh, S. Cyrus ;
Halladay, Jason S. .
DRUG METABOLISM AND DISPOSITION, 2014, 42 (05) :813-817
[23]   Inhibitory Effects of Deoxypodophyllotoxin from Anthriscus sylvestris on Human CYP2C9 and CYP3A4 [J].
Lee, Sang Kyu ;
Kim, Yoon ;
Jin, Changbae ;
Lee, Seung Ho ;
Kang, Mi Jeong ;
Jeong, Tae Cheon ;
Jeong, Seo Young ;
Kim, Dong-Hyun ;
Yoo, Hye Hyun .
PLANTA MEDICA, 2010, 76 (07) :701-704
[24]   In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose [J].
Tai, GY ;
Farin, F ;
Rieder, MJ ;
Dreisbach, AW ;
Veenstra, DL ;
Verlinde, CLMJ ;
Rettie, AE .
PHARMACOGENETICS AND GENOMICS, 2005, 15 (07) :475-481
[25]   Clinical effect of CYP2C9*5/*6 genotype on a patient's warfarin dose requirement [J].
Quinn, Alison L. H. ;
Liko, Ina ;
Lee, James C. .
PHARMACOGENOMICS, 2017, 18 (11) :1051-1057
[26]   Inhibitory effects of cytochrome P450 enzymes CYP2C8, CYP2C9, CYP2C19 and CYP3A4 by Labisia pumila extracts [J].
Pan, Yan ;
Tiong, Kai Hung ;
Abd-Rashid, Badrul Amini ;
Ismail, Zakiah ;
Ismail, Rushli ;
Mak, Joon Wah ;
Ong, Chin Eng .
JOURNAL OF ETHNOPHARMACOLOGY, 2012, 143 (02) :586-591
[27]   Inhibitory effects of phthalimide derivatives on the activity of the hepatic cytochrome P450 monooxygenases CYP2C9 and CYP2C19 [J].
Kolukisaoglu, Uener ;
Wendler, Christian ;
Goerdes, Dirk ;
Diener, Annette ;
Thurow, Kerstin .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2010, 25 (06) :876-886
[28]   Inhibitory effects of angiotensin receptor Blockers on CYP2C9 activity in human liver Microsomes [J].
Kamiyama, Emi ;
Yoshigae, Yasushi ;
Kasuya, Atsushi ;
Takei, Makoto ;
Kurihara, Atsushi ;
Ikeda, Toshihiko .
DRUG METABOLISM AND PHARMACOKINETICS, 2007, 22 (04) :267-275
[29]   Effects of rare CYP2C9 alleles on stable warfarin doses in Chinese Han patients with atrial fibrillation [J].
Wang, Dongxu ;
Dai, Da-Peng ;
Wu, Hualan ;
Chong, Jia ;
Lu, You ;
Yin, Ruoyun ;
Zhao, Xinlong ;
Zhao, Anxu ;
Yang, Jiefu ;
Chen, Hao .
PHARMACOGENOMICS, 2020, 21 (14) :1021-1031
[30]   Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction [J].
Fang, Zhong-Ze ;
Zhang, Yan-Yan ;
Ge, Guang-Bo ;
Huo, Hong ;
Liang, Si-Cheng ;
Yang, Ling .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (02) :193-199